US4400375A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tobramycin-double stranded RNA complex suitable for inducing interferon
Assignee: Eli Lilly and Co
•
Filing: 1981-11-23
•
Granted: 1983-08-23
•
Expires: 2001-11-23
Abstract
Abstract A complex is described which is useful in inducing interferon production, in activating peritoneal macrophages, and in inhibiting the proliferation and migration of tumor cells, which complex comprises natural or synthetic double stranded RNA and tobramycin.
Inventors
- 👤 Richard J. Douthart
- 👤 Walter J. Kleinschmidt
- 👤 Richard M. Schultz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 13:17
CPC Classifications
A; A61; A61K; A61K38/00; A61K31/00; A61K31/70; A61P; A61P35/00; C; C07; C07H; C07H21/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
29 words
A complex comprising (a) natural or synthetic double stranded RNA and (b) tobramycin in a molar ratio of tobramycin to double stranded RNA phosphorus of at least about 1:1.
Claim 2
Dependent Claim
29 words
A complex comprising (a) natural or synthetic double stranded RNA and (b) tobramycin in a molar ratio of tobramycin to double stranded RNA phosphorus of at least about 1:1.
Claim 3
Dependent Claim
14 words
Complex of claim 1, in which the double stranded RNA is of natural origin.
Claim 4
Dependent Claim
14 words
Complex of claim 2, in which the double stranded RNA source is Penicillium chrysogenum.
Claim 5
Dependent Claim
23 words
Complex of claim 3, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 12:1 to about 1:1.
Claim 6
Dependent Claim
23 words
Complex of claim 3, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 9:1 to about 6:1.
Claim 7
Dependent Claim
48 words
A pharmaceutical composition suitable for inducing interferon comprising in combination with a pharmaceutically acceptable carrier an interferon-inducing amount of a complex of (a) natural or synthetic double stranded RNA and (b) tobramycin in a molar ratio of tobramycin to double stranded RNA phosphorus of at least about 1:1.
Claim 8
Dependent Claim
48 words
A pharmaceutical composition suitable for inducing interferon comprising in combination with a pharmaceutically acceptable carrier an interferon-inducing amount of a complex of (a) natural or synthetic double stranded RNA and (b) tobramycin in a molar ratio of tobramycin to double stranded RNA phosphorus of at least about 1:1.
Claim 9
Dependent Claim
14 words
Composition of claim 6, in which the double stranded RNA is of natural origin.
Claim 10
Dependent Claim
14 words
Composition of claim 7, in which the double stranded RNA source is Penicillium chrysogenum.
Claim 11
Dependent Claim
23 words
Composition of claim 8, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 12:1 to about 1:1.
Claim 12
Dependent Claim
23 words
Composition of claim 8, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 9:1 to about 6:1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-22 | 1987-02-21 | 1987-08-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-22 | 1991-02-21 | 1991-08-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-22 | 1995-02-21 | 1995-08-23 | $7700.00 | Window Closed / Lapsed |